A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
NCT05055063
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Myeloma
Interventions
DRUG:
Belantamab mafodotin
Sponsor
M.D. Anderson Cancer Center